TIDMPYC

RNS Number : 9284I

Physiomics PLC

17 December 2020

17 December 2020

Physiomics plc

("Physiomics" or "the Company")

Partnership with TRHC's DoseMeRx(R) Targeting Precision Dosing for Oncology Medications

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions, today announces it has entered into a partnership with Tabula Rasa HealthCare(R) ("TRHC") (NASDAQ:TRHC), a healthcare technology company advancing the field of medication safety. Through this initiative, Physiomics' personalised docetaxel model will be integrated into TRHC's market-leading precision dosing solution, DoseMeRx(R). Both parties expect positive feedback from this initial trial with the next step being a commercial agreement.

Cancer remains one of the leading causes of death in developed countries and one of the most significant areas of spend for health systems. There are many effective cancer drugs; but, it is well established that, given the same dose, variations between individuals mean that different amounts of drug reach their tumours.

Using measurements of the amount of drug in a patient's blood to guide what dose they should receive has been shown to improve efficacy and reduce side effects. The tests, however, are difficult to obtain in oncology since they are expensive and not standardised. Physiomics' personalised dosing models rely only on inexpensive, standard blood tests that could help doctors and pharmacists in making decisions about the dose of cancer drugs for individual patients.

TRHC's DoseMeRx enables healthcare providers to optimise dosing and streamline operations, reduce adverse drug events, and decrease costs. The unique DoseMeRx platform incorporates Bayesian science to guide the safe and effective dosing of 42 different drugs.

Physiomics Chief Executive Officer, Jim Millen, MD, said, "Initially, we will focus on the drug docetaxel, which is commonly used to treat prostate, breast and other cancers. However, one of our goals is to establish how this could potentially be extended to apply to other drugs and cancer types. We partnered with TRHC because its DoseMeRx solution has been the leader in the personalised dosing field for several years, and they have demonstrated the ability to not only lead the science, but to make it accessible for those who can benefit from it. We look forward to the results of the trial and potentially entering into a revenue generating contract in due course."

TRHC Chief Scientific Officer Jacques Turgeon, BPharm, PhD, added, "The focus of the collaboration is on delivering better outcomes for cancer patients. Incorporating this new science into DoseMeRx will enable clinicians to more effectively predict the timing of serious adverse effects, such as neutropenia, that are commonly observed in patients receiving chemotherapy. We have seen a great deal of success in infectious diseases through the use of DoseMeRx, and we are excited to expand this into oncology."

Charles Cornish, TRHC's Executive Vice President, Hospital Business Unit, said, "Through this partnership, we're bringing together Physiomics' expertise in oncology precision medication dosing with our experience in developing easy-to-use clinical decision support software. Combined with our network of healthcare providers throughout the United States and the world, this partnership will further support the safe use of these medications in clinical practice."

The information contained within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014.

Enquiries:

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

Strand Hanson Ltd (NOMAD)

Richard Tulloch & James Dance

+44 (0)20 7409 3494

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0)20 3764 2341

TRHC Media Contact

Dianne L. Semingson

dsemingson@trhc.com

1+215-870-0829

Notes to Editor

About Physiomics

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour(TM) technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 80 projects, involving over 40 targets and 70 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.

About Tabula Rasa HealthCare

Tabula Rasa HealthCare (TRHC) (NASDAQ:TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize performance to improve patient outcomes, reduce hospitalizations, lower healthcare costs, and manage risk. Medication risk management is TRHC's lead offering, and its cloud-based software applications provide solutions for a range of payers, providers, and other healthcare organizations. For more information, visit TRHC.com

About DoseMeRx

DoseMeRx (R) is a Tabula Rasa HealthCare solution and the first precision dosing software developed specifically for clinical practice. DoseMeRx's clinical decision support solutions empower healthcare providers to optimize dosing of high-risk parenteral medications to streamline operations, reduce adverse drugs events, decrease costs, and improve patient outcomes. For more information, visit doseme-rx.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCFZMMZGVKGGZZ

(END) Dow Jones Newswires

December 17, 2020 09:00 ET (14:00 GMT)